Ketamine: stimulating antidepressant treatment?

Gin S. Malhi; Yulisha Byrow; Frederick Cassidy; Andrea Cipriani; Koen Demyttenaere; Mark A Frye; Michael Gitlin; Sidney H Kennedy; Terence A Ketter; Raymond W Lam; Rupert McShane; Alex J Mitchell; Michael J Ostacher; Sakina J Rizvi; Michael E Thase; Mauricio Tohen

doi:10.1192/bjpo.bp.116.002923

Ketamine: stimulating antidepressant treatment?

Gin S. Malhi, Yulisha Byrow, Frederick Cassidy, Andrea Cipriani, Koen Demyttenaere, Mark A Frye, Michael Gitlin, Sidney H Kennedy, Terence A Ketter, Raymond W Lam, Rupert McShane, Alex J Mitchell, Michael J Ostacher, Sakina J Rizvi, Michael E Thase, Mauricio Tohen

Research output: Contribution to journal › Editorial › peer-review

25 Citations (Scopus)

180 Downloads (Pure)

Abstract

The appeal of ketamine - in promptly ameliorating depressive symptoms even in those with non-response - has led to a dramatic increase in its off-label use. Initial promising results await robust corroboration and key questions remain, particularly concerning its long-term administration. It is, therefore, timely to review the opinions of mood disorder experts worldwide pertaining to ketamine's potential as an option for treating depression and provide a synthesis of perspectives - derived from evidence and clinical experience - and to consider strategies for future investigations.

Original language	English
Pages (from-to)	e5-e9
Number of pages	5
Journal	BJPsych Open
Volume	2
Issue number	3
DOIs	https://doi.org/10.1192/bjpo.bp.116.002923
Publication status	Published - May 2016
Externally published	Yes

Bibliographical note

Copyright the Publisher 2016. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Access to Document

10.1192/bjpo.bp.116.002923

Publisher version (open access).pdfFinal published version, 520 KB

Cite this

@article{d522b5658b354ffcb48580e1ece8c7c5,

title = "Ketamine: stimulating antidepressant treatment?",

abstract = "The appeal of ketamine - in promptly ameliorating depressive symptoms even in those with non-response - has led to a dramatic increase in its off-label use. Initial promising results await robust corroboration and key questions remain, particularly concerning its long-term administration. It is, therefore, timely to review the opinions of mood disorder experts worldwide pertaining to ketamine's potential as an option for treating depression and provide a synthesis of perspectives - derived from evidence and clinical experience - and to consider strategies for future investigations.",

author = "Malhi, {Gin S.} and Yulisha Byrow and Frederick Cassidy and Andrea Cipriani and Koen Demyttenaere and Frye, {Mark A} and Michael Gitlin and Kennedy, {Sidney H} and Ketter, {Terence A} and Lam, {Raymond W} and Rupert McShane and Mitchell, {Alex J} and Ostacher, {Michael J} and Rizvi, {Sakina J} and Thase, {Michael E} and Mauricio Tohen",

note = "Copyright the Publisher 2016. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",

year = "2016",

month = may,

doi = "10.1192/bjpo.bp.116.002923",

language = "English",

volume = "2",

pages = "e5--e9",

journal = "BJPsych Open",

issn = "2056-4724",

publisher = "Cambridge University Press (CUP)",

number = "3",

}

TY - JOUR

T1 - Ketamine

T2 - stimulating antidepressant treatment?

AU - Malhi, Gin S.

AU - Byrow, Yulisha

AU - Cassidy, Frederick

AU - Cipriani, Andrea

AU - Demyttenaere, Koen

AU - Frye, Mark A

AU - Gitlin, Michael

AU - Kennedy, Sidney H

AU - Ketter, Terence A

AU - Lam, Raymond W

AU - McShane, Rupert

AU - Mitchell, Alex J

AU - Ostacher, Michael J

AU - Rizvi, Sakina J

AU - Thase, Michael E

AU - Tohen, Mauricio

N1 - Copyright the Publisher 2016. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2016/5

Y1 - 2016/5

N2 - The appeal of ketamine - in promptly ameliorating depressive symptoms even in those with non-response - has led to a dramatic increase in its off-label use. Initial promising results await robust corroboration and key questions remain, particularly concerning its long-term administration. It is, therefore, timely to review the opinions of mood disorder experts worldwide pertaining to ketamine's potential as an option for treating depression and provide a synthesis of perspectives - derived from evidence and clinical experience - and to consider strategies for future investigations.

AB - The appeal of ketamine - in promptly ameliorating depressive symptoms even in those with non-response - has led to a dramatic increase in its off-label use. Initial promising results await robust corroboration and key questions remain, particularly concerning its long-term administration. It is, therefore, timely to review the opinions of mood disorder experts worldwide pertaining to ketamine's potential as an option for treating depression and provide a synthesis of perspectives - derived from evidence and clinical experience - and to consider strategies for future investigations.

UR - http://www.scopus.com/inward/record.url?scp=85017096136&partnerID=8YFLogxK

U2 - 10.1192/bjpo.bp.116.002923

DO - 10.1192/bjpo.bp.116.002923

M3 - Editorial

C2 - 27703782

SN - 2056-4724

VL - 2

SP - e5-e9

JO - BJPsych Open

JF - BJPsych Open

IS - 3

ER -

Ketamine: stimulating antidepressant treatment?

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this